Sign up
Pharma Capital

OptiBiotix Health signs manufacturing and supply agreement with US Pharma Lab

Per Rehne, chief commercial director of OptiBiotix Health plc (LON:OPTI), discusses with Proactive's Andrew Scott a manufacturing and supply agreement they've signed with a US-based probiotic maker for its LPLDL probiotic strain.

Rehne says under the agreement, US Pharma Lab Inc (USPL) will be granted non-exclusive rights to manufacture and supply formulations containing the LPLDL strain.

 

View full OPTI profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.